2007.02.16 (Fri)
°äÅÁ»Ò¿ÇÃǤª¤è¤Ó°äÅÁ»Ò¿·¿¤Ë¤Ä¤¤¤Æ
°äÅÁ»Ò¿ÇÃǤª¤è¤Ó°äÅÁ»Ò¿·¿¤Ë¤Ä¤¤¤Æ
µ¡¥½ø
¡¡°äÅÁ»Ò¿ÇÃǤȤϡ¢°äÅÁÉÂhereditary disease¤ä´â¤Î¤è¤¦¤Ê¸ÄÂÎÆâ¤Î°äÅÁ»Ò¤Î¹½Â¤ÊѲ½¤ä¡¢¥¦¥¤¥ë¥¹´¶À÷¤Ê¤É¤Î³°³¦¤«¤é¤Î¿·¤¿¤Ê°äÅÁ»Ò¤Î¿¯Æþ¤Ëµ¯°ø¤¹¤ë¼À´µ¤Ë¤ª¤¤¤Æ¡¢É°ø¤È¤Ê¤ë°äÅÁ»Ò¤ÎʬÀϤ˴ð¤Å¤¤¤Æ¹Ô¤¦¿ÇÃǤǤ¢¤ë¡£¤¹¤Ê¤ï¤Á¡¢°äÅÁ»Ò¿ÇÃÇ(¸¡ºº)¤¬Å¬±þ¤È¤Ê¤ë¤Î¤Ï¡¢
1.´¶À÷¾É¤Î°äÅÁ»Ò¸¡ºº
2.°äÅÁɤΰäÅÁ»Ò¸¡ºº
3.¤·ì´ï¼ðáç¤Î°äÅÁ»Ò¸¡ºº
4.¸Ç·Á¼ðáç¤Î°äÅÁ»Ò¸¡ºº
5.°äÅÁ»Ò¿·¿²òÀÏ
¡¡¤Ê¤É¤Ç¤¢¤ë¡£
¡¡½¾Íè¤ÎÀ¸²½³ØÅª¸¡ºº¤äÎ×¾²Åª¿ÇÃǤÏÊѰ۰äÅÁ»Ò¤Îɽ¸½·¿¤Ë´ð¤Å¤¯¤¬¡¢°äÅÁ»Ò¿ÇÃǤǤϰäÅÁ»Ò¤½¤Î¤â¤Î¤òÄ´¤Ù¤ë¤¿¤á¡¢È¯¾ÉÁ°¿ÇÃÇpreclinical diagnosis¤¢¤ë¤¤¤Ï½ÐÀ¸Á°¿ÇÃÇprenatal diagnosis¡¢¤µ¤é¤ËÊݰø¼Ô¿ÇÃÇcarrier diagnosis¤â²Äǽ¤È¤Ê¤Ã¤¿¡£¤Þ¤¿°äÅÁɤǤϡ¢¸¡ºº¤¹¤ë¡´ï¤òÌä¤ï¤Ê¤¤¤¿¤á¡¢ÂÛ»ù¤Ç¤Ïå°ÌÓ¤äÍÓ¿åºÙ˦¡¢½ÐÀ¸¸å¤ÏËö¾¿·ìÇò·ìµå¤Ê¤É¤òÍѤ¤¤Æ¿ÇÃǤ¹¤ë¤³¤È¤¬²Äǽ¤Ç¤¢¤ë¡£¶ñÂÎŪ¤Ë¤Ï¡¢¶ñÂÎŪ¤Ë¤Ï¡¢1)ȯü¼Ô¤Î³ÎÄê¿ÇÃÇ¡¢2)²È²¤ÎÊݰø¼Ô¿ÇÃÇ¡¢3)¼¡»Ò¤Î½ÐÀ¸Á°¿ÇÃÇ¡¢¤Ê¤É¤ÎÌÜŪ¤Ç¹Ô¤ï¤ì¤ë¡£°Ê²¼¤Ç¤Ï¡¢°äÅÁ»Ò¿ÇÃǤª¤è¤Ó°äÅÁ»Ò¿·¿¤Î³µÍפˤĤ¤¤Æµ¤·¤Æ¤ß¤¿¤¤¤È»×¤¦¡£
¶¡¥°äÅÁ»Ò¿ÇÃǤÎÊýË¡
¡¡°äÅÁ»Ò¤Î¹½Â¤ÊѲ½¤È¤·¤Æ¤Ï¡¢ÅÀÆÍÁ³ÊѰÛpoint mutation¡¤·ç¼ºdeletion¡¤½ÅÊ£duplication¡¤ÁýÉýamplification¡¤ÁÞÆþinsertion¡¤µÕ°Ìinversion¡¤Å¾ºÂtranslocation¤Ê¤É¤¬¤¢¤ê¡¢°äÅÁ»Ò¸¡ºº¤Ç¤Ï¡¢¤³¤ì¤é¤ò¥µ¥¶¥ó¥Ö¥í¥Ã¥ÈË¡¤äPCRË¡¡¢LAMPË¡¤Ê¤É¤Ë¤è¤Ã¤Æ¸¡½Ð¤¹¤ë¡£Èù¾¯¤ÊÊѲ½¤ËÂФ·¤Æ¤Ï¡¢±ö´ðÇÛÎó·èÄêË¡sequencing¤âÊ»ÍѤµ¤ì¤ë¡£°äÅÁ»Ò¸¡ºº¤Î¼ïÎà¤È¤·¤Æ¤Ï¡¢
1¡¥DNA²òÀÏ
¡¡1¡Ë¥µ¥¶¥ó¥Ö¥í¥Ã¥È¡¢RFLP
¡¡2¡ËPCR¡¦PCR-SSCPË¡
¡¡3¡Ë¥Þ¥¤¥¯¥í¥µ¥Æ¥é¥¤¥È/¥ß¥Ë¥µ¥Æ¥é¥¤¥ÈÉÔ°ÂÄêÀ¤Î¸¡½Ð
¡¡4¡ËFISHË¡¡¦CGHË¡
2¡¥RNA²òÀÏ
¡¡1¡Ë¥Î¡¼¥¶¥ó¥Ö¥í¥Ã¥È¡¦RT-PCR
¡¡2¡Ëin situ hybridization
¡¡3¡ËDifferential Display
3¡¥ºÇ¿·²òÀϵ»½Ñ
¡¡1¡ËLAMPË¡
¡¡2¡ËICAN TM Ë¡
¡¡3¡ËNASBAË¡
¡¡¤Ê¤É¤¬¤¢¤ë¡£¶áǯ¡¢Çò·ìɤä°À¥ê¥ó¥Ñ¼ð¤Ê¤É¤Î¤·ì´ï¼ðáç¤ÎʬÌî¤Ç¤Ï°äÅÁ»ÒÊѰۤθ¦µæ¤¬¹Ô¤ï¤ì¡¢Â¿¤¯¤Î¼À´µ¤Ë¤ª¤¤¤ÆÆÃ°ÛŪ¤Ê°äÅÁ»Ò°Û¾ï¤¬Æ±Äꤵ¤ì¤Ä¤Ä¤¢¤ë¡£¤³¤ì¤Ë´ð¤Å¤¥µ¥¶¥óË¡¤äPCRË¡¤Ë¤è¤ê°äÅÁ»Ò¿ÇÃǤ¬²Äǽ¤È¤Ê¤Ã¤¿¡£¤½¤Î¸å¼£ÎÅÈ¿±þÀ¤Îɾ²Á¤ËÄêÎÌŪ°äÅÁ»Ò¿ÇÃǤ¬Æ³Æþ¤µ¤ì¡¢¤½¤ÎÍÍÑÀ¤¬¿ô¿¤¯Êó¹ð¤µ¤ì»Ï¤á¤Æ¤¤¤ë¡£
¡¡°ÊÁ°¤ÏÄêÎÌŪ°äÅÁ»Ò¿ÇÃÇË¡¤Ë¤ÏÊ£»¨¤«¤ÄÏ«ÎϤòÍפ¹¤ë¸¡½ÐË¡¤·¤«¤Ê¤«¤Ã¤¿¤¬¡¢¶áǯ´ÊÊØ¤Ç·ÐºÑŪ¤Êreal time quantitative PCRË¡¡ÊRQ-PCR¡Ë¤¬Åо줷¡¢¹¤¯Æü¾ïÎ×¾²¤ËƳÆþ¤µ¤ì¤Ä¤Ä¤¢¤ë¡£·ì±ÕÎΰè¤Ç¤ÏRQ-PCR¤Ï¥ê¥ó¥Ñµå¼õÍÆÂΰäÅÁ»ÒºÆ¹½À®¡ÊIg,TCR¡Ë¡¤Çò·ìÉÂÆÃ°ÛŪͻ¹ç°äÅÁ»Ò¡ÊBcr /Abl , PML /RAR¦Á , AML1 / MTG8 , Bcl2 /IgH ¤Ê¤É¡Ë¡¤Çò·ìÉÂÈóÆÃ°ÛŪ°äÅÁ»Ò¡ÊWT-1 °äÅÁ»Ò¤Ê¤É¡Ë¤òÍѤ¤¤¿minimal residual disease¡ÊMRD¡Ë¤Î¸¡½Ð¤Î¤ß¤Ê¤é¤º¡¢¥¦¥¤¥ë¥¹¡¤¿¿¶Ý¡¤Peumocystis carinii ¤Ê¤É¤Î´¶À÷¾É¤Î¿ÇÃǤä¥â¥Ë¥¿¥ê¥ó¥°¤Ë¤âÍøÍѤµ¤ì»Ï¤á¤Æ¤¤¤ë¡£
·¡¥°äÅÁ»Ò¿·¿¤È¤Ï
¡¡Æ±°ì¼ï¤Ë°¤¹¤ëÀ¸Êª¤Ç¤¢¤Ã¤Æ¤â¸Ä¡¹¤Î¥²¥Î¥à¤Î±ö´ðÇÛÎó¤Ï¿¼ï¿ÍͤǤ¢¤ë¡£¤½¤ÎÊѲ½¤Ï¡¢É½¸½·¿¤ËÉÂŪ±Æ¶Á¤òÍ¿¤¨¤ë¾ì¹ç¤ÈÍ¿¤¨¤Ê¤¤¾ì¹ç¤È¤¬¤¢¤ë¤¬¡¢¸å¼Ô¤Ç¤«¤Ä¿Í¸ý¤Î1¡ó°Ê¾å¤ÎÉÑÅ٤Ǹºß¤¹¤ë°äÅÁ»Ò¤ÎÊѰۤò°äÅÁ»Ò¿·¿¤È¤¤¤¦¡£
¡¡¸½ºß¡¢Â¿°ø»Ò°äÅÁɤȤδط¸¤Ç¡¢ÍÍѤȤµ¤ì¤Æ¤¤¤ë°äÅÁ»Ò¿·¿¤Ï2¼ïÎढ¤ë¡£°ì¤Ä¤ÏDNA¤ÎÇÛÎó¤Î1²Õ½ê¤Î±ö´ðÇÛÎó¤¬Ê̤ʱö´ð¤ËÊѤï¤Ã¤Æ¤¤¤ë¡¢°ì±ö´ð¿·¿¡Êsingle nucleotide polymorphism¡Ë¤Ç¡¢SNP¤È¤·¤Ð¤·¤Ðɽµ¤µ¤ì¥¹¥Ë¥Ã¥×¤Èȯ²»¤µ¤ì¤ë¤â¤Î¤Ç¤¢¤ë¡£
¡¡¤â¤¦°ì¤Ä¤Ï2¸Ä¤«¤é4¸Ä¤Îñ°Ì¤ÎÇÛÎ󤬿ô²ó¤«¤é¿ô½½²ó·«¤êÊÖ¤¹¡¢¡Ö·«¤êÊÖ¤·ÇÛÎó¡×¤Î·«¤êÊÖ¤·²ó¿ô¤Î¸Ä¿Íº¹¤Ç¡¢¥Þ¥¤¥¯¥í¥µ¥Æ¥é¥¤¥È¿·¿¡Êmicrosatellite polymorphism¡Ë¤È¸Æ¤Ð¤ì¤ë¤â¤Î¤Ç¤¢¤ë¡£SNP¤Ï¥Ò¥È¥²¥Î¥à¾å¤ÇºÇ¤â¿ô¿¤¯Â¸ºß¤¹¤ë¿·¿¤Ç¡¢Ê¿¶ÑÌó1000±ö´ð¤´¤È¤Ë°ì¥ö½ê¤ß¤é¤ì¡¢¤ª¤½¤é¤¯¥²¥Î¥àÁ´ÂΤǤÏ200Ëü°Ê¾å¤Ï¤¢¤ë¤È¤ß¤é¤ì¤Æ¤¤¤ë¡£¥Þ¥¤¥¯¥í¥µ¥Æ¥é¥¤¥È¿·¿¤Ï3Ëü¤«¤é10Ëü±ö´ð¤Ë°ì¥ö½ê¤¢¤ë¤È¤µ¤ì¡¢Ìó½½Ëü¥Ò¥È¥²¥Î¥à¤Ë¸ºß¤¹¤ë¤È¤µ¤ì¤ë¡£SNP¤Ï¥Þ¥¤¥¯¥í¥µ¥Æ¥é¥¤¥È¤è¤ê¡¢¸Ä¡¹¤Î¾ðÊóÎ̤Ͼ¯¤Ê¤¤¤¬¿ô¤¬Â¿¤¤¤¿¤á¡¢Éµ¤¤È¤Î´Ø·¸¤äÌô¤Î¸ú²Ì¤Ê¤ÉÎ×¾²¤ËÌòΩ¤Ä¤â¤Î¤¬¸«¤Ä¤«¤ë¤Î¤Ç¤Ï¤Ê¤¤¤«¤È´üÂÔ¤ò½¸¤á¤Æ¤¤¤ë¡£
¡¡SNP¤Ï°äÅÁ»Ò¤ÎÃæ¤ÎÀê¤á¤ë°ÌÃ֤ˤè¤Ã¤Æ¡¢¶èÊ̤µ¤ì¤Æ¸Æ¤Ð¤ì¤ë¤³¤È¤¬¤¢¤ë¡£°äÅÁ»Ò¤Î¥×¥í¥â¡¼¥¿¡¼Îΰè¡Ê°äÅÁ»Ò¤Îȯ¸½Î̤òÀ©¸æ¤¹¤ëÎΰè¡Ë¤Ë¤¢¤ë¤â¤Î¤òrSNP¡¢°äÅÁ»Ò¤ÎÃÁÇò¤ËËÝÌõ¤µ¤ì¤ëÉôʬ¤Ë¤¢¤ë¤â¤Î¤ÏcSNP¤È¤è¤Ð¤ì¡¢°äÅÁ»Ò¤Î¥¤¥ó¥È¥í¥ó¡ÊÃÁÇò¤ÎÇÛÎó¤ä°äÅÁ»ÒÄ´À°¤Ë¤¢¤Þ¤ê´Ø·¸¤·¤Ê¤¤¡Ë¤Ë¤¢¤ë¤â¤Î¤ÏiSNP¤È¸Æ¤Ð¤ì¤Æ¤¤¤ë¡£¤³¤Î¤¦¤Á¡¢rSNP¤ÈcSNP¤¬°äÅÁ»Ò¤Îµ¡Ç½¤Ë´Ø·¸¤¹¤ë²ÄǽÀ¤¬¹â¤¤¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£SNP¤ò´Þ¤à°äÅÁ»Ò¿·¿¤¬¸ÄÀ¤Ë±þ¤¸¤¿°åÎŤˤȤäÆÉ¬ÍפʾðÊó¤È¹Í¤¨¤é¤ì¤ë¤Î¤Ï¡¢¤³¤ì¤érSNP¤äcSNP¤Ê¤É¤¬¡¢¤¿¤È¤¨¤Ð·ì°µ¡¢·ìÅü¡¢¥¢¥ì¥ë¥®¡¼¤òµ¯¤³¤·¤ä¤¹¤¤¤«¤É¤¦¤«¡¢µ¤Æ»²áÉÒÀ¡¢Ìô¤Î¸ú²Ì¤Ê¤É¤Î¸Ä¿Íº¹¤Î¾¯¤Ê¤¯¤È¤â°ìÉô¤òÀâÌÀ¤Ç¤¤ë¤Î¤Ç¤Ï¤Ê¤¤¤«¤È¸À¤¦´üÂÔ¤¬¤¢¤ë¤¿¤á¡¢¤È¹Í¤¨¤é¤ì¤ë¡£
¸¡¥°äÅÁ»Ò¿·¿¤Èɽ¸½·¿¤Î´ØÏ¢À¤Ë¤ª¤±¤ë¶ñÂÎÎã
¡¡¶áǯ¡¢¥Ò¥ÈÈîËþ´ØÏ¢°äÅÁ»Ò¥Þ¥Ã¥Ô¥ó¥°¤ÎµÞ®¤ÊȯŸ¤Ë¤è¤ê¡¢139¼ï¤¢¤Þ¤ê¤ÎÈîËþ´ØÏ¢°äÅÁ»Ò¤¬Ç§¤á¤é¤ì¡¢¤½¤ÎÃæ¤Ç¥Ý¥¸¥Æ¥£¥Ö¤ÊÊó¹ð¤È¤·¤Æ90¼ïÎà(synder¤é2004)¤¬³Îǧ¤µ¤ì¤Æ¤¤¤ë¡£¤·¤«¤·¡¢¥á¥¿¥Ü¥ê¥Ã¥¯¥·¥ó¥É¥í¡¼¥à¤Îȯ¾É¤ËÂФ·¤Æ´Ä¶Åª¤ª¤è¤Ó°äÅÁŪÍ×°ø¤¬¤É¤ÎÄøÅٱƶÁ¤·¤Æ¤¤¤ë¤Î¤«¤Ë¤Ä¤¤¤Æ¤Ï¡¢¸½ºßÌÀ¤é¤«¤Ç¤Ï¤Ê¤¤¡£ÈîËþ´ØÏ¢°äÅÁ»Ò¤Î1¤Ä¤µ¤ì¤ë¦Â3¥¢¥É¥ì¥Ê¥ê¥ó¥ì¥»¥×¥¿¡¼°äÅÁ»Ò1)¤Ë´ØÏ¢¤·¤Æ¡¢¤½¤Î»ºÊª¤Ç¤¢¤ë¦Â-3¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂΤϡ¢¤ª¤â¤Ë»éËÃÁÈ¿¥¤Ç¸«¤é¤ì¡¢»éËÃʬ²ò¤ÈǮȯÀ¸¤ÎÄ´Àá¤Ë´ØÍ¿¤¹¤ë¡£¦Â-¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂΤÏG¥¿¥ó¥Ñ¥¯¼Á¤ÎƯ¤¤òÄ̤·¤Æ¡¢¥¨¥Ô¥Í¥Õ¥ê¥ó¤ª¤è¤Ó¥Î¥ë¥¨¥Ô¥Í¥Õ¥ê¥ó¤¬Í¶Æ³¤¹¤ë¥¢¥Ç¥Ë¥ë»À´Ä²½¹ÚÁǤγèÀ²½¤Ë´ØÍ¿¤¹¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£
¡¡¤Þ¤¿¡¢UCP12)°äÅÁ»Ò¤Ë´ØÏ¢¤·¤Æ¡¢¥ß¥È¥³¥ó¥É¥ê¥¢Ã¦¶¦Ìò¥¿¥ó¥Ñ¥¯¼Á(UCP)¤Ï¡¢¥ß¥È¥³¥ó¥É¥ê¥¢±¢¥¤¥ª¥óôÂÎ¥¿¥ó¥Ñ¥¯¼Á(MACP)¤Î¥Õ¥¡¥ß¥ê¡¼¤Ë°¤¹¤ë¡£UCP¤ÏATP¹çÀ®¤«¤é»À²½Åª¥ê¥ó»À²½¤òÀÚ¤êÎ¥¤·¡¢¥¨¥Í¥ë¥®¡¼¤òÇ®¤È¤·¤ÆÈ¯»¶¤·¤Æ¤·¤Þ¤¦¡£¤³¤ì¤Ï¥ß¥È¥³¥ó¥É¥ê¥¢¤«¤é¤Î¥×¥í¥È¥óϳ½Ð¤È¤â¤è¤Ð¤ì¤ë¡£UCP¤Ï¥ß¥È¥³¥ó¥É¥ê¥¢Ëì¤ÎÆâ¦¤«¤é³°Â¦¤Ø¤Î±¢¥¤¥ª¥ó¤Î°Üư¤È¡¢¥×¥í¥È¥ó¤Î³°Â¦¤«¤éÆâ¦¤Ø¤Î´Ôή°Üư¤òÂ¥¿Ê¤¹¤ë¡£¤½¤ì¤ÏÓ®ÆýÎàºÙ˦¤Ë¤ª¤±¤ë¥ß¥È¥³¥ó¥É¥ê¥¢ËìÅṲ̋ò¹ß²¼¤µ¤»¤â¤¹¤ë¡£°Û¤Ê¤ëUCP¤Ë¤ÏÁÈ¿¥ÆÃ°ÛÀ¤¬¤¢¤ê¡¢¤É¤Î¤è¤¦¤Ë¤·¤ÆUCP¤¬H+/OH-¤òÍ¢Á÷¤¹¤ë¤Î¤«¤Ë´Ø¤¹¤ëÀµ³Î¤ÊÊýË¡¤Ï¤ï¤«¤Ã¤Æ¤¤¤Ê¤¤¡£UCP¤ÏMACP¤ÎÁêÆ±¥¿¥ó¥Ñ¥¯¼ÁÎΰè¤ò3¤Ä¤â¤Ä¡£Ç®¤òȯÀ¸¤µ¤»¤ë¤Î¤ËÆÃ²½¤·¤¿ÁÈ¿¥¤Ç¤¢¤ë³ì¿§»éËÃÁÈ¿¥¤Ç¡¢¤³¤Î°äÅÁ»Ò¤Ïȯ¸½¤µ¤ì¤ë¡£
¡¡DIO2(Thr92Ala deiodinase type 2)¤Ï¡¢¥¤¥ó¥¹¥ê¥óÄñ¹³À¤È´ØÏ¢¤·¤Æ¤¤¤ë¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë3)¡£
1)Ochi M, Osawa H, Onuma H, Murakami A, et al The absence of evidence for major effects of the frequent SNP +299G>A in the resistin gene on susceptibility to insulin resistance syndrome associated with Japanese type 2 diabetes. :Diabetes Res Clin Pract. 2003 Sep;61(3):191-8.
2)Yamada T, Katagiri H, Ishigaki Y. et al Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms: neuronal involvement in food-intake regulation. :Cell Metab. 2006 Mar;3(3):223-9
3)Mentuccia D, Thomas MJ, Coppotelli G, et al The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. : Thyroid. 2005 Nov;15(11):1223-7.
¥é¥ó¥¥ó¥°ÅÐÏ¿Ãæ¤Ë¤Ä¤¡¢¤´¶¨ÎϤè¤í¤·¤¯¤ª´ê¤¤¤·¤Þ¤¹¡£
¥È¥Ã¥×¥Ú¡¼¥¸¤Ø
¥ê¥ó¥¯
¤ª°å¼Ô¤Ë¤Ê¤ë¤Î¤ÏÂçÊѤǤ¹¤Í
¤³¤Îµ»ö¤Î¥È¥é¥Ã¥¯¥Ð¥Ã¥¯URL
¢ªhttp://medmerry.blog80.fc2.com/tb.php/155-56b1df25
¤³¤Îµ»ö¤Ë¥È¥é¥Ã¥¯¥Ð¥Ã¥¯¤¹¤ë(FC2¥Ö¥í¥°¥æ¡¼¥¶¡¼)
¤³¤Îµ»ö¤Ë¥È¥é¥Ã¥¯¥Ð¥Ã¥¯¤¹¤ë(FC2¥Ö¥í¥°¥æ¡¼¥¶¡¼)
¤³¤Îµ»ö¤Ø¤Î¥È¥é¥Ã¥¯¥Ð¥Ã¥¯
| BLOGTOP |







